Evolution of genetic assessment for BRCA-associated gynaecologic malignancies: a Canadian multisociety roadmap

The landscape of genetic testing in ovarian cancer patients has changed dramatically in recent years. The therapeutic benefits of poly ADP-ribose polymerase (PARP) inhibitors in treatment of BRCA1/2-related ovarian cancers has resulted in an increased demand and urgency for genetic testing results,...

Descripción completa

Detalles Bibliográficos
Autores principales: McCuaig, Jeanna M, Stockley, Tracy L, Shaw, Patricia, Fung-Kee-Fung, Michael, Altman, Alon D, Bentley, James, Bernardini, Marcus Q, Cormier, Beatrice, Hirte, Hal, Kieser, Katharina, MacMillan, Andree, Meschino, Wendy S, Panabaker, Karen, Perrier, Renee, Provencher, Diane, Schrader, Kasmintan A, Serfas, Kimberly, Tomiak, Eva, Wong, Nora, Young, Sean S, Gotlieb, Walter Henri, Hoskins, Paul, Kim, Raymond H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Cancer Genetics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6119348/
https://www.ncbi.nlm.nih.gov/pubmed/30042185
http://dx.doi.org/10.1136/jmedgenet-2018-105472

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6119348/
https://www.ncbi.nlm.nih.gov/pubmed/30042185
http://dx.doi.org/10.1136/jmedgenet-2018-105472

Ejemplares similares